Improved immune status corresponds with long-term decline of quantitative serum hepatitis B surface antigen in HBV/HIV co-infected patients.

@article{Arendt2012ImprovedIS,
  title={Improved immune status corresponds with long-term decline of quantitative serum hepatitis B surface antigen in HBV/HIV co-infected patients.},
  author={Eduard Arendt and Jerzy Jaroszewicz and J{\"u}rgen K. Rockstroh and Dirk Meyer-Olson and Behrend Johan Zacher and Ingmar Mederacke and Michael P. Manns and Heiner Wedemeyer and Markus Cornberg and Karsten Wursthorn},
  journal={Viral immunology},
  year={2012},
  volume={25 6},
  pages={442-7}
}
In HBV/HIV-co-infected individuals, the course of hepatitis B is aggravated, leading to higher morbidity and mortality rates. Increasing evidence suggests an important role for hepatitis B surface antigen (HBsAg) quantification in monitoring treatment efficacy in HBV monoinfection. However, data concerning any HBsAg decline during treatment of HBV/HIV coinfection are limited. Fifty-one HBV/HIV-co-infected patients were retrospectively followed for a mean of 43 months (median 2 years… CONTINUE READING